Document is current
Any future updates will be listed below
-
Authors
Solmi, Marco https://orcid.org/0000-0003-4877-7233
Fornaro, Michele https://orcid.org/0000-0002-9647-0853
Caiolo, Stefano
Lussignoli, Marialaura https://orcid.org/0009-0003-3968-9060
Caiazza, Claudio
De Prisco, Michele https://orcid.org/0000-0002-2032-1181
Solini, Niccolo https://orcid.org/0000-0002-1749-2908
de Bartolomeis, Andrea https://orcid.org/0000-0002-3188-5652
Iasevoli, Felice https://orcid.org/0000-0002-7051-5013
Pigato, Giorgio
Del Giovane, Cinzia
Cipriani, Andrea https://orcid.org/0000-0001-5179-8321
Correll, Christoph U. https://orcid.org/0000-0002-7254-5646
- License Information
-
More Information
Article History
Received: 31 December 2023
Revised: 22 August 2024
Accepted: 28 August 2024
First Online: 18 December 2024
Competing interests
: MS received honoraria/has been a consultant for AbbVie, Angelni, Lundbeck, Otsuka. MF received honoraria from the American Society of Clinical Psychopharmacology (ASCP) for his speaker activities, and from Angelini, Lundbeck, Bristol Meyer Squibb, and Boehringer-Ingelheim. AdB has received research support from Janssen, Lundbeck, and Otsuka and lecture fees for educational meetings from Chiesi, Lundbeck, Roche, Sunovion, Viatris, Recordati, Angelini, and Takeda; he has served on advisory boards for Eli Lilly, Jansen, Lundbeck, Otsuka, Roche, and Takeda, Chiesi, Recordati, Angelini, Viatris. CUC has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Adock Ingram, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Sage, Seqirus, SK Life Science, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Tolmar, Vertex, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Mindpax, and Quantic. AC is supported by the National Institute for Health Research (NIHR) Oxford Cognitive Health Clinical Research Facility, by an NIHR Research Professorship (grant RP-2017-08-ST2-006), by the NIHR Oxford and Thames Valley Applied Research Collaboration and by the NIHR Oxford Health Biomedical Research Centre (grant NIHR203316). The views expressed are those of the authors and not necessarily those of the UK National Health Service, the NIHR, or the UK Department of Health. The other authors have none to disclose in conjunction with the present work.
